MARKET

TTNP

TTNP

Titan Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2190
-0.0015
-0.68%
After Hours: 0.2200 +0.001 +0.46% 18:49 04/08 EDT
OPEN
0.2235
PREV CLOSE
0.2205
HIGH
0.2235
LOW
0.2150
VOLUME
3.80M
TURNOVER
--
52 WEEK HIGH
2.180
52 WEEK LOW
0.1420
MARKET CAP
20.47M
P/E (TTM)
-0.2224
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TTNP stock price target is 8.50 with a high estimate of 16.00 and a low estimate of 1.000.

EPS

TTNP News

More
  • Edited Transcript of TTNP earnings conference call or presentation 30-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 04/01 17:23
  • Penny Stocks to Buy Using Technical Analysis for April 2020
  • Investopedia · 03/31 17:43
  • The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions
  • Benzinga · 03/31 12:26
  • Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/30 23:43

Industry

Pharmaceuticals
+2.78%
Pharmaceuticals & Medical Research
+2.83%

Hot Stocks

Symbol
Price
%Change

About TTNP

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.
More

Webull offers kinds of Titan Pharmaceuticals, Inc. stock information, including NASDAQ:TTNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTNP stock news, and many more online research tools to help you make informed decisions.